Sorafenib is a multikinase inhibitor that inhibits angiogenesis and tumor proliferation by interfering with the binding of serine/threonine kinases to receptor tyrosine kinases and acts on both cancer cells and endothelial cells [49,50]. Here, NTRK1 is linked to cancer.